Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, August 15, 2023
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
[ Tue, Aug 15th 2023
] - WOPRAI
Seamus Fernandez Maintained (VERV) at Strong Buy with Decreased Target to $55 on, Aug 15th, 2023
Seamus Fernandez of Guggenheim, Maintained "Verve Therapeutics, Inc." (VERV) at Strong Buy with Decreased Target from $56 to $55 on, Aug 15th, 2023.
Seamus has made no other calls on VERV in the last 4 months.
There are 3 other peers that have a rating on VERV. Out of the 3 peers that are also analyzing VERV, 1 agrees with Seamus's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Reiterated at Hold and Held Target at $31 on, Friday, August 11th, 2023
These are the ratings of the 2 analyists that currently disagree with Seamus
- Whitney Ijem of "Canaccord Genuity" Reiterated at Strong Buy and Held Target at $29 on, Friday, June 16th, 2023
- Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $35 on, Tuesday, May 16th, 2023
